Cytomedix is well positioned to achieve a leadership position in the field of advanced tissue regeneration technologies, with the continuing development and marketing of biologically active products to treat patients with debilitating and life-threatening conditions. Its synergistic Angel® and AutoloGel products place Cytomedix as a leader in PRP technology with FDA indications in the areas of orthopedics and wound care. Both product lines have proven clinical benefits and significant growth potential.
Recently, GBI Research released its Diabetes Therapeutics Market to 2017 report favorably reviewing the global diabetes therapeutic industry and offering that companies like Cytomedix, Inc. are poised for rapid growth.
BiotechStockTrader.com then expounded upond these findings with their own in depth analysis of Cytomedix. Pointing out that diabetic foot ulcers effect 15 percent of patients with diabetes, BiotechStockTrader predicts strong growth for the company, commenting,
"This is where Cytomedix, a leader in the commercialization of innovative autologous therapies that promote healing by harnessing the innate regenerative capacity of platelets and adult stem cells, offers a revolutionary technology that outstrips current wound care therapies and provides a convenient and cost-effective new approach."
See the full presentation from BiotechStockTrader.com below: